PMID- 37931898
OWN - NLM
STAT- Publisher
LR  - 20240329
IS  - 1715-3360 (Electronic)
IS  - 0008-4182 (Linking)
DP  - 2023 Nov 3
TI  - Risk of ocular adverse events with aromatase inhibitors.
LID - S0008-4182(23)00317-4 [pii]
LID - 10.1016/j.jcjo.2023.10.013 [doi]
AB  - OBJECTIVE: Aromatase inhibitors (AIs) are a class of medications used for 
      adjuvant treatment of breast cancer. Recent case reports suggest that AIs may be 
      associated with various ocular adverse events (AEs). This study evaluates the 
      risk of ocular AEs in patients who take AIs. METHOD: Disproportionality analysis 
      was performed using data from the U.S. Food and Drug Administration's Adverse 
      Events Reporting System database from 2004 to 2022. All cases of vitreomacular 
      traction, macular edema, retinal deposits, retinal artery occlusion, macular 
      hole, retinal hemorrhage, uveitis, retinal tear, retinal detachment, dry eye 
      disease, blepharitis, and optic neuropathy were searched for the 3 AIs 
      anastrozole, letrozole, and exemestane. A search also was performed on 
      trastuzumab as a control. Reported odds ratios (RORs) and corresponding 95% CIs 
      were computed. RESULTS: We identified 322 ocular AEs of interest for the 3 AIs 
      and 55 for trastuzumab. Anastrozole had the most AEs (n = 163) and was found to 
      have strong associations with vitreomacular traction (ROR = 665; 95% CI, 
      352-1255), macular edema (ROR = 37; 95% CI, 25-54), retinal deposits (ROR = 11; 
      95% CI, 2-77), and uveitis (ROR = 6; 95% CI, 4-9). Letrozole had strong 
      associations with retinal deposits (ROR = 8, 95% CI, 1-57) and retinal artery 
      occlusion (ROR = 6; 95% CI, 3-11). Exemestane had a strong association with 
      macular holes (ROR = 10; 95% CI, 3-30). CONCLUSION: Disproportionality analysis 
      revealed an increased risk of ocular AEs with each of the AIs. This study calls 
      for clinicians, especially oncologists and ophthalmologists, to be vigilant in 
      patients who are on AI therapy, allowing them to provide prompt interventions to 
      mitigate further ocular morbidities.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Feng, Zhao Xun
AU  - Feng ZX
AD  - Department of Ophthalmology, University of Ottawa, Ottawa, ON.
FAU - Sriranganathan, Aswen
AU  - Sriranganathan A
AD  - Department of Ophthalmology, University of Ottawa, Ottawa, ON.
FAU - Lo, Cody
AU  - Lo C
AD  - Department of Ophthalmology, University of Ottawa, Ottawa, ON.
FAU - Liu, Victoria
AU  - Liu V
AD  - Department of Ophthalmology, University of Ottawa, Ottawa, ON.
FAU - Maberley, David
AU  - Maberley D
AD  - Department of Ophthalmology, University of Ottawa, Ottawa, ON.
FAU - Etminan, Mahyar
AU  - Etminan M
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, BC.. Electronic address: etminanm@amil.ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20231103
PL  - England
TA  - Can J Ophthalmol
JT  - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
JID - 0045312
SB  - IM
EDAT- 2023/11/07 00:42
MHDA- 2023/11/07 00:42
CRDT- 2023/11/06 19:20
PHST- 2023/05/30 00:00 [received]
PHST- 2023/09/13 00:00 [revised]
PHST- 2023/10/10 00:00 [accepted]
PHST- 2023/11/07 00:42 [pubmed]
PHST- 2023/11/07 00:42 [medline]
PHST- 2023/11/06 19:20 [entrez]
AID - S0008-4182(23)00317-4 [pii]
AID - 10.1016/j.jcjo.2023.10.013 [doi]
PST - aheadofprint
SO  - Can J Ophthalmol. 2023 Nov 3:S0008-4182(23)00317-4. doi: 
      10.1016/j.jcjo.2023.10.013.